GOERING Richard R. (US),ГОЕРИНГ Ричард Р. (US),MATsUMURA Akira (JP),МАЦУМУРА Акира (JP),ShAO Bin (US),ШАО Бин (US),TAODA Eshijuki (JP),ТАОДА Ёшиюки (JP),TsUNO Naoki (JP),ЦУНО Наоки (JP),UAJTKhEAD Dzho,GOERING RICHARD R.,ГОЕРИНГ Ричард Р.,MATSUMURA AKIRA,МАЦУМУРА Акира,SHAO BIN,ШАО Бин,TAODA ESHIJUKI,ТАОДА Ёшиюки,TSUNO NAOKI,ЦУНО Наоки,UAJTKHEAD DZHON UILJAM FREHNK,УАЙТХЕАД Джон Уильям Фрэнк,JAO TSZ
申请号：
RU2010108388/04
公开号：
RU0002488585C2
申请日:
2008.08.29
申请国别(地区):
RU
年份:
2013
代理人:
摘要：
FIELD: medicine, pharmaceutics.SUBSTANCE: invention refers to substituted quinoxaline-type piperidine compounds of formula or to a pharmaceutically acceptable derivative thereof, wherein: Y1 represents O； Q is specified in condensed benzo or pyridino； each R2 is independently specified in: (a) -halogen or -CN； (b) -(C1-C6)alkyl； a is an integer specified in 0, 1 or 2； a dash line in a 6-member ring containing a nitrogen atom which is condensed with Q group means the presence or absence of a bond, and when the dash line means the absence of the bond, then R3, and one R4 are absent； R3 is specified in: (a) -H； each R4 is independently specified in: (a) -H； or (b) - halogen or CN； or (c) -X, -(C1-C6)alkyl-X, -(5- or 6-member)heterocyclyl-X or -(5- or 6-member)heterocyclyl-(C1-C6)alkyl-X； or (d) -C(=Y)X, -C(=Y)T3, -C(=Y)YX, - C(=Y)YT3, -C(-Y)N(T1)(T2), -C(=Y)N(R9)CN, -C(=Y)N(R9)X, -C(=Y)N(R9)YH, -C(=Y)N(R9)YX, -C(=Y)N(R9)YCH2X, -C(-Y)N(R9)YCH2CH2X or -C(=Y)N(R9)S(K))2T3； or (e) -N(R9)X, -N(R9)-CH2X, -N(R9)-CH2CH2X, -N(R9)CH2N(R9)C(=N(R12))N(R12)2, -N(R9)-CH2CH2N(R9)C(=N(RI2))N(R12)2, -N(T1)(T2), -N(T3)C(=Y)T3, -N(T3)C(=Y)YT3, -N(T3)C(=Y)N(T1)(T2), -N(T3)S(=O)2T3 or -N(T3)S(=O)2N(T1)(T2)； X represents: (a) -H, -( C1-C6)alkyl, -(C2-C6)alkenyl, -(C1-C6)alkoxy, -(C3-C7)cycloalkyl, -(5- or 6-member)heterocycle or -(7-10-member)bicycloheterocycle each of which is unsubstituted or substituted with 1, 2 or 3 of optionally substituted R8 groups； or (b) -phenyl, -naphthalenyl, or -(5- or 6-member)heteroaryl each of which is unsubstituted or substituted with 1 or 2 of independently specified in R7 groups； each Y is independently specified in O； A and B are independently specified in: (a) -H； or (c) A-B together can form a (C2-C6)bridge each can optionally contain -HC=CH- or -O- in a (C2-C6)bridge； wherein the 6-member ring containing a nitrogen atom which is condensed with Q group can be found in the endo- or exo- configuration in relation to the A-B bridge； or (d) A-B together c
